Effective letermovir prophylaxis of cmv infection post allogeneic hematopoietic cell transplantation: results from the french temporary authorization of use compassionate program - Université de Lille Accéder directement au contenu
Article Dans Une Revue Journal of Clinical Virology Année : 2022

Effective letermovir prophylaxis of cmv infection post allogeneic hematopoietic cell transplantation: results from the french temporary authorization of use compassionate program

Pascal Turlure
  • Fonction : Auteur
Nathalie Benard
  • Fonction : Auteur
Camille Liautard
  • Fonction : Auteur

Résumé

We report the results of the French Temporary Authorization of Use (ATU) compassionate program of letermovir for primary prophylaxis conducted in 21 transplant centers. Patients were CMV seropositive allogeneic hematopoietic cell transplantation recipients and at high risk for CMV infection. Primary prophylaxis was defined as initiation of letermovir between day 0 and day +28 post-transplant. Between November 2017 and January 2019, 96 patients with a median age of 56 years received letermovir and follow-up data were available for 78 patients. The median time from transplant to letermovir initiation was 4 days, and the median duration of exposure to letermovir was 78 days, with 57 patients still on treatment at the cutoff date. Letermovir was temporarily discontinued in 4 patients (5.1%) and stopped in 39 patients (50.0%), in most cases due to planned end of treatment (n = 16, 20.5%). Fifteen patients (19.2%) each presented one positive CMV PCR, in median 13 days after letermovir initiation. Clinically significant CMV infection was reported in 5 patients (6.4%). No CMV disease was reported. At least one adverse drug reaction was reported for 12 patients (15.4%). In this early access program, letermovir was effective with comparable results of the phase 3 study with a low rate of clinically significant CMV infection, including in patients who were at high-risk for CMV infection.
Fichier principal
Vignette du fichier
2022-02-15.pdf (843.4 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03989762 , version 1 (15-02-2023)

Licence

Paternité

Identifiants

Citer

David Beauvais, Christine Robin, Anne Thiebaut, Sophie Alain, Valerie Coiteux, et al.. Effective letermovir prophylaxis of cmv infection post allogeneic hematopoietic cell transplantation: results from the french temporary authorization of use compassionate program. Journal of Clinical Virology, 2022, Journal of clinical virology the official publication of the Pan American Society for Clinical Virology, 148, pp.105106. ⟨10.1016/j.jcv.2022.105106⟩. ⟨hal-03989762⟩
22 Consultations
13 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More